2024
Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation
Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Díaz-Fernández P, Gómez-García de Soria V, Stevens J, Kfuri-Rubens R, Shao Y, Kooshesh K, Powell K, Ji H, Hernandez G, Abelin J, Klaeger S, Forman C, Clauser K, Sarkizova S, Braun D, Penter L, Kim H, Lane W, Oliveira G, Kean L, Li S, Livak K, Carr S, Keskin D, Muñoz-Calleja C, Ho V, Ritz J, Soiffer R, Neuberg D, Stewart C, Getz G, Wu C. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation. Nature Biotechnology 2024, 43: 971-982. PMID: 39169264, PMCID: PMC11912513, DOI: 10.1038/s41587-024-02348-3.Peer-Reviewed Original ResearchAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationCell transplantationEffect of allogeneic hematopoietic cell transplantationIdentification of minor histocompatibility antigensOutcomes of allogeneic hematopoietic cell transplantationOccurrence of acute GVHDPost-transplant disease recurrenceGraft-versus-host diseaseWhole-exome sequencing of germline DNASequencing of germline DNAGraft-versus-leukemiaT-cell alloreactivityGraft-versus-hostMinor histocompatibility antigensWhole-exome sequencingAcute GVHDPulmonary GVHDAllo-HCTDisease recurrenceHistocompatibility antigensClinical outcomesValidation cohortGermline DNAGVHDA phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
Al Malki M, Keyzner A, Suh H, Popat U, Gill S, Chen Y, Solh M, Gowda L, Buonomo E, Wang Y, Murray J, MacBeath G, Barton D, Chattopadhyay S, Reshef R. A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Journal Of Clinical Oncology 2024, 42: tps2678-tps2678. DOI: 10.1200/jco.2024.42.16_suppl.tps2678.Peer-Reviewed Original ResearchHematopoietic cell transplantationMinimal residual diseaseEngineered T cell therapiesPatient hematopoietic cellsT-cell therapyMinor histocompatibility antigensHematopoietic cellsHLA-A*02:01Residual diseaseCell transplantationHematologic malignanciesPost-HCTT cellsHistocompatibility antigensTreatment armsCAR-T cell therapyAllogeneic hematopoietic cell transplantationHematopoietic cell transplant patientsPrevent disease relapseRelapse post-HCTDose-limiting toxicityDisease-free survivalEngineered T cellsHaploidentical donor transplantationSurrogate of efficacy
2013
Alloimmunization To HLA Class I Antigens But Not H-Y Antigens Is Associated With Transfusion In Children With Sickle Cell Disease
Nickel R, Hendrickson J, Kean L, Yee M, Bray R, Gebel H, Miklos D, Horan J. Alloimmunization To HLA Class I Antigens But Not H-Y Antigens Is Associated With Transfusion In Children With Sickle Cell Disease. Blood 2013, 122: 39. DOI: 10.1182/blood.v122.21.39.39.Peer-Reviewed Original ResearchHematopoietic stem cell transplantMinor histocompatibility antigensHuman leukocyte antigenSickle cell diseaseHLA class I antibodiesClass I human leukocyte antigenClass I antibodiesPediatric SCD patientsRBC transfusionHLA class IGraft rejectionSCD patientsY antigenHLA antibodiesChronic transfusionIgG antibodiesI antibodiesCell diseaseClass I HLA antibodiesHLA class II antibodiesClass II human leukocyte antigenRed blood cell transfusionManagement of SCDClass IHLA-identical transplantation
2011
Memory T cells from minor histocompatibility antigen–vaccinated and virus-immune donors improve GVL and immune reconstitution
Li N, Matte-Martone C, Zheng H, Cui W, Venkatesan S, Tan HS, McNiff J, Demetris AJ, Roopenian D, Kaech S, Shlomchik WD. Memory T cells from minor histocompatibility antigen–vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood 2011, 118: 5965-5976. PMID: 21917752, PMCID: PMC3228506, DOI: 10.1182/blood-2011-07-367011.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell ProliferationGraft vs Leukemia EffectHematopoiesisImmunologic MemoryLymphocytesLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMiceMice, Inbred C3HMice, Inbred C57BLMice, KnockoutMinor Histocompatibility AntigensT-LymphocytesTissue DonorsTransplantation ImmunologyUp-RegulationVaccinationConceptsDonor T cellsMemory T cellsImmune reconstitutionT cellsAllogeneic hematopoietic stem cell transplantationSingle minor histocompatibility antigenHematopoietic stem cell transplantationVirus-immune donorsLeukemia cellsStem cell transplantationMinor histocompatibility antigensT-cell manipulationChronic myeloid leukemiaLymphocytic choriomeningitis virusGVL effectLeukemia relapseAdoptive immunotherapyMinor histocompatibilityTreatment failureCell transplantationMyeloid leukemiaHistocompatibility antigensGVHDVaccinationInfectionAIP1 Prevents Graft Arteriosclerosis by Inhibiting Interferon-&ggr;–Dependent Smooth Muscle Cell Proliferation and Intimal Expansion
Yu L, Qin L, Zhang H, He Y, Chen H, Pober JS, Tellides G, Min W. AIP1 Prevents Graft Arteriosclerosis by Inhibiting Interferon-&ggr;–Dependent Smooth Muscle Cell Proliferation and Intimal Expansion. Circulation Research 2011, 109: 418-427. PMID: 21700930, PMCID: PMC3227522, DOI: 10.1161/circresaha.111.248245.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAorta, AbdominalAorta, ThoracicArteriosclerosisCell MovementCell ProliferationCells, CulturedDisease Models, AnimalHumansInterferon-gammaJanus Kinase 2MaleMiceMice, KnockoutMinor Histocompatibility AntigensMuscle, Smooth, Vascularras GTPase-Activating ProteinsReceptors, InterferonSignal TransductionSTAT1 Transcription FactorSTAT3 Transcription FactorTime FactorsTunica IntimaVascular GraftingConceptsASK1-interacting protein-1Neointima formationTransplantation modelIntimal expansionSingle minor histocompatibility antigenSmooth muscle cell proliferationMinor histocompatibility antigensAortic transplantation modelAorta transplantation modelMuscle cell proliferationVSMC accumulationDonor graftsGraft arteriosclerosisIntimal formationIntravenous administrationHistocompatibility antigensVSMC proliferationMouse aortaVSMC migrationIFNProliferative diseasesEndothelial cellsProtein 1Cell proliferationJAK-STAT signaling
2009
Donor APCs Promote Gvhd in MHC-Mismatched Transplants by Indirectly Presenting Host Minor Histocompatibility Antigens.
Wang X, Martone C, Demetris A, McNiff J, Shlomchik W. Donor APCs Promote Gvhd in MHC-Mismatched Transplants by Indirectly Presenting Host Minor Histocompatibility Antigens. Blood 2009, 114: 689. DOI: 10.1182/blood.v114.22.689.689.Peer-Reviewed Original ResearchAntigen presenting cellsBALB/c miceHost minor histocompatibility antigensCD4 cellsMinor histocompatibility antigensT cellsC miceAcute GVHDAllogeneic MHCChronic GVHDDonor BMHistocompatibility antigensIndirect presentationFemale recipientsT cell receptor transgenic T cellsDay 7Bone marrow/stem cell transplantationFemale BALB/c miceHost antigen presenting cellsMale BALB/c miceRecipient antigen presenting cellsBALB/c modelAlloreactive CD4 cellsPrime T cellsStem cell transplantation
2007
320: In vivo activation of APCs with TLR ligands and tissue damage rather than amount of host APCs are critical factors that determine DLI-mediated GVL reactivity and GVHD in MHC-matched minor histocompatibility antigen (mHAg)-mismatched chimeras
Radojcic V, Skarica M, Murphy G, Luznik L. 320: In vivo activation of APCs with TLR ligands and tissue damage rather than amount of host APCs are critical factors that determine DLI-mediated GVL reactivity and GVHD in MHC-matched minor histocompatibility antigen (mHAg)-mismatched chimeras. Transplantation And Cellular Therapy 2007, 13: 116-117. DOI: 10.1016/j.bbmt.2006.12.325.Peer-Reviewed Original ResearchMinor histocompatibility antigensGVL reactivityHost APCsTLR ligandsHistocompatibility antigensTissue damageVivo activationAPCGVHDAntigenMHC
2004
Donor APCs are required for maximal GVHD but not for GVL
Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D, McNiff J, Shlomchik WD. Donor APCs are required for maximal GVHD but not for GVL. Nature Medicine 2004, 10: 987-992. PMID: 15286785, DOI: 10.1038/nm1089.Peer-Reviewed Original ResearchConceptsDonor antigen-presenting cellsAntigen-presenting cellsCD8 cellsMouse modelDonor major histocompatibility complex (MHC) class IBone marrowDonor-derived antigen-presenting cellsChronic phase chronic myelogenous leukemiaHematopoietic antigen-presenting cellsRecipient antigen-presenting cellsHost antigen-presenting cellsMajor histocompatibility complex class IAlloreactive CD8 cellsRecipients of MHCHistocompatibility complex class IDonor-derived cellsMinor histocompatibility antigensChronic myelogenous leukemiaDeficient bone marrowComplex class IHost diseaseGVHDHistocompatibility antigensMyelogenous leukemiaInitial priming
2003
Role of CXCR3-induced donor T-cell migration in acute GVHD
Duffner U, Lu B, Hildebrandt G, Teshima T, Williams D, Reddy P, Ordemann R, Clouthier S, Lowler K, Liu C, Gerard C, Cooke K, Ferrara J. Role of CXCR3-induced donor T-cell migration in acute GVHD. Experimental Hematology 2003, 31: 897-902. PMID: 14550805, DOI: 10.1016/s0301-472x(03)00198-x.Peer-Reviewed Original ResearchConceptsRole of CXCR3T cellsAcute GVHDDonor T cell expansionDonor T cell migrationDonor T cellsExpression of CXCR3GVHD target organsDonor cellsEffector T cellsBone marrow transplantation modelDonor T-cell functionMinor histocompatibility antigensT cell expansionWild-type B6Chemokine receptor CXCR3T cell functionWild-type T cellsWild-type donor cellsT cell migrationMigration of donorWild-type donorsAcute graftHost diseaseBMT recipients
1992
Role of Gamma/Delta T Cells as Positive Regulators of Alpha/Beta TCR+ Effector T Cells in Allergic Contact Sensitivity
Askenase PW, Ptak W. Role of Gamma/Delta T Cells as Positive Regulators of Alpha/Beta TCR+ Effector T Cells in Allergic Contact Sensitivity. International Archives Of Allergy And Immunology 1992, 99: 246-251. PMID: 34167199, DOI: 10.1159/000236258.Peer-Reviewed Original ResearchCutaneous contact sensitivityEffector T cellsCS-effector T cellsT cell receptorΓδ T cellsT cellsCS responsesContact sensitivityGamma/delta T cellsCell transferCS effector cellsDelta T cellsMinor histocompatibility antigensAdoptive cell transferΑβ T cellsAllergic contact sensitivityTCR mAbEffector cellsΓδ TΑβ TAlpha/betaRabbit complementHistocompatibility antigensVitro treatmentCell receptor
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply